EGFR G796D mutation mediates resistance to osimertinib
Metrics: PDF 1534 views | HTML 2373 views | ?
Di Zheng1,*, Min Hu2,*, Yu Bai2, Xuehua Zhu2, Xuesong Lu3, Chunyan Wu4, Jiying Wang1, Li Liu1, Zheng Wang3, Jian Ni1, Zhenfan Yang2 and Jianfang Xu1
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai, China
2IMED Asia, AstraZeneca, Shanghai, China
3Research and Development Information, AstraZeneca, Shanghai, China
4Department of Pathology, Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai, China
*These authors contributed equally to this work
Jianfang Xu, email: email@example.com
Zhenfan Yang, email: Pamela.Yang@astrazeneca.com
Keywords: EGFR, NSCLC, osimertinib, drug resistance, G796D
Received: March 08, 2017 Accepted: May 04, 2017 Published: May 16, 2017
Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound. Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification. However, a comprehensive view is still missing. In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism. Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.